FUDANZHANGJIANG
- Country
- Ownership
- -
- Established
- 1996-11-11
- Employees
- 948
- Market Cap
- -
- Website
- http://www.fd-zj.com
- Introduction
The company was founded in November 1996 in the Zhangjiang Hi-Tech Park in Pudong, Shanghai, with well-known enterprises such as Shanghai Pharmaceutical Group Co., Ltd. as shareholders of the company. It is mainly engaged in innovative research and development, manufacturing and marketing of biomedicine. Main products: Dermatological products, anti-tumor products, etc. Corporate honors: Jiangsu High-tech Enterprise, 2017 Economic Outstanding Contribution Award, Shanghai Enterprise Technology Center, etc.
Clinical Trials
24
Trial Phases
4 Phases
Drug Approvals
6
Drug Approvals
Doxorubicin Hydrochloride Liposome Injection
- Product Name
- 盐酸多柔比星脂质体注射液
- Approval Number
- 国药准字H20123224
- Approval Date
- Feb 14, 2023
Doxorubicin Hydrochloride Liposome Injection
- Product Name
- 盐酸多柔比星脂质体注射液
- Approval Number
- 国药准字H20084432
- Approval Date
- Feb 14, 2023
Downs Syndrome Screening System
- Product Name
- 唐氏综合征产前筛查系统
- Approval Number
- 国药准字S20040017
- Approval Date
- Mar 17, 2004
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 100
- Registration Number
- NCT06715319
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 350
- Registration Number
- NCT06519370
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2Papillomavirus Infectionsp16 Protein
- Interventions
- Drug: PlaceboDrug: Aminolaevulinic acid (500-mg bottle)Drug: Aminolaevulinic acid (750-mg bottle)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Target Recruit Count
- 119
- Registration Number
- NCT06439433
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 162
- Registration Number
- NCT06424665
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shanghai East Hospital, Shanghai, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）
- Conditions
- 5-aminolevulinic AcidMalignant Glioma of Brain
- Interventions
- Drug: 5 Aminolevulinic Acid
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 80
- Registration Number
- NCT06417281
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next